Status In progress
Process STA 2018
ID number 1493

Project Team

Project lead Louise Jafferally

Email enquiries

Evidence Review Group / Assessment Group BMJ Technology Assessment Group (BMJ-TAG), BMJ

Consultees

Companies sponsors Amgen (carfilzomib)
Others NHS England
  Welsh Government
Patient carer groups Myeloma UK
Professional groups Association of Cancer Physicians
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists

Commentators

Assessment group Janssen (bortezomib) (confidentiality agreement signed, participating)
  Sanofi (dexamethasone) (confidentiality agreement signed, participating)
  Advanz (dexamethasone) (confidentiality agreement not signed, not participating)
  Allergan (dexamethasone) (confidentiality agreement not signed, not participating)
  Aspen (dexamethasone) (confidentiality agreement not signed, not participating)
  Aspire Pharma (bortezomib, dexamethasone) (confidentiality agreement not signed, not participating)
  Bausch & Lomb (dexamethasone) (confidentiality agreement not signed, not participating)
  Celgene (lenalidomide, pomalidomide) (confidentiality agreement not signed, not participating)
  Ethypharm UK (dexamethasone) (confidentiality agreement not signed, not participating)
  Glenmark Pharmaceuticals Europe (dexamethasone)(confidentiality agreement not signed, not participating)
  Hameln pharmaceuticals (dexamethasone) (confidentiality agreement not signed, not participating)
  Hospira UK (dexamethasone) (confidentiality agreement not signed, not participating)
  Novartis (dexamethasone, panobinostat) (confidentiality agreement not signed, not participating)
  Panpharma UK (dexamethasone) (confidentiality agreement not signed, not participating)
  Rayner (dexamethasone) (confidentiality agreement not signed, not participating)
  Rosemont (dexamethasone) (confidentiality agreement not signed, not participating)
  Sun Pharma (bortezomib) (confidentiality agreement not signed, not participating)
  Teva UK (dexamethasone) (confidentiality agreement not signed, not participating)
  Thea (dexamethasone) (confidentiality agreement not signed, not participating)
  Thornton & Ross (bortezomib) (confidentiality agreement not signed, not participating)
  Wockhardt (dexamethasone) (confidentiality agreement not signed, not participating)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Healthcare Improvement Scotland
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
30 August 2019 In progress, Appraisal in progress
30 August 2019 Invitation to participate

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance